Accueil   Diary - News   All news Biom’up sees a strong commercial uptake in HEMOBLASTTM Bellows in the US and Europe

Biom’up sees a strong commercial uptake in HEMOBLASTTM Bellows in the US and Europe

 

Biom’up (the “Company”), a specialist in surgical hemostasis, announces today an update on its first months of commercialization of HEMOBLAST Bellows in the US and Europe and confirms a strong uptake among hospitals and surgeons.


Since its introduction to the US market in July 2018, 26 hospitals have purchased HEMOBLAST Bellows, indicating that the product has already successfully passed hospital evaluations. In total, more than 240 US hospitals are now also currently evaluating HEMOBLAST Bellows, up from 140 in mid-September.

 

Read the press release

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree